Baby Safety / Compounds / Nano-hydroxyapatite (n-HAp)

Is Nano-hydroxyapatite (n-HAp) safe for babies and kids?

Elevated risk for kids

Infants are more vulnerable to Nano-hydroxyapatite (n-HAp) than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What is nano-hydroxyapatite (n-hap)?

The IUPAC name is pentacalcium;hydroxide;triphosphate.

Also known as: Durapatite, 1306-06-5, Calcium hydroxyapatite, Radiesse.

IUPAC name
pentacalcium;hydroxide;triphosphate
CAS number
1306-06-5
Molecular formula
Ca5HO13P3
Molecular weight
502.3 g/mol
SMILES
[OH-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2]
PubChem CID
14781

Risk for babies

Elevated risk

Infants are more vulnerable to Nano-hydroxyapatite (n-HAp) than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Context-dependent

Pregnancy alters the metabolism and distribution of Nano-hydroxyapatite (n-HAp), potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.

No specific reproductive toxicity data identified, but pregnancy-specific safety data is limited for most chemicals. Precautionary minimization of exposure is recommended.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

3 regulatory and scientific bodies have classified Nano-hydroxyapatite (n-HAp). The classifications differ — that's the data.

AgencyYearClassificationNotes
EU SCCS2023Safe in oral cosmetics (non-nano or rod-shaped nano ≤10%); needle-shaped nano form potentially genotoxic — not safe
Japan1980Approved dental ingredient since 1980s (Sangi/Apagard)
Canada2024Under Health Canada assessment for cosmetic use

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter nano-hydroxyapatite (n-hap)

  • Personal Care
  • Medical Device

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Nano-hydroxyapatite (n-HAp):

  • Fluoride (sodium fluoride, stannous fluoride)
    Trade-offs: Well-established efficacy but fluorosis risk at high intake. Nano-HAp may be preferred in fluoride-restricted markets (Japan).
    Relative cost: 0.1× nano-HAp
  • Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
    Trade-offs: Milk protein derivative — not suitable for dairy-allergic patients. Prescription product in some markets.
    Relative cost: 2× fluoride toothpaste

Frequently asked questions

Is nano-hydroxyapatite (n-hap) safe for kids?

Infants are more vulnerable to Nano-hydroxyapatite (n-HAp) than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What should I do if my child is exposed to nano-hydroxyapatite (n-hap)?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Why do regulators disagree about nano-hydroxyapatite (n-hap)?

Nano-hydroxyapatite (n-HAp) has been classified by 3 agencies including EU SCCS, Japan, Canada, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.

See Nano-hydroxyapatite (n-HAp) in the baby app

Look up products containing nano-hydroxyapatite (n-hap), compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (1)
  1. —

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →